Dabush DR, Shepshelovich D, Shochat T, et al. - Findings suggested an association of shorter restaging intervals with a higher magnitude of effect on progression-free survival (PFS), but not overall survival (OS). The impact of the restaging interval on PFS quantification is critical for the design and interpretation of randomized controlled trials.

• There were 89 studies in total, with 95 comparisons and 44,901 patients.

• The magnitude of the PFS advantage was greater in trials with short restaging intervals compared to long restaging intervals, but this difference did not approach the pre-defined statistical significance criterion.

• In pre-specified subgroups, including non-first-line trials, trials with drugs replacing standard treatment, and studies performed in exclusively human epidermal growth factor receptor 2 positive disease, a short restaging interval was associated with a significantly larger magnitude of effect on PFS.

• With both short and long restaging periods, the magnitude of the OS improvement was comparable.